Dr. Reddy’s excels in generics, biosimilars, and active pharmaceutical ingredients (APIs), with a portfolio spanning therapeutic areas like gastroenterology, oncology, cardiovascular, and pain management. It invests heavily in R&D (8-15% of sales annually), driving innovation and securing exclusive generic drug approvals, such as 180-day exclusivity in the U.S. market. Strategic acquisitions, like Trigenesis Therapeutics and UCB SA’s brands, and partnerships, such as with Alvotech for biosimilars, enhance its global footprint and product offerings.
Financially, Dr. Reddy’s reported ₹31,229 crore in revenue and ₹5,448 crore in profit for FY2024, with a market cap of ~₹98,132 crore. Despite fluctuating net profit margins (7-20% over FY2015-FY2024), its integrated supply chain, regulatory expertise, and focus on high-growth areas like nutraceuticals and cell therapy position it for sustained growth. However, challenges include regulatory hurdles, competition in generics, and ethical criticism for continued operations in Russia.
Latest News on Dr. Reddy’s Laboratories
Dr Reddy’s relies on biosimilars and weight-loss medication launches to compensate for declining US dominance of Revlimid.
Dr. Reddy’s Laboratories, a leading Indian pharmaceutical company, is shifting its focus towards biosimilars and a new weight-loss drug to drive growth as its exclusivity for the generic version of Revlimid in the US market is set to expire. Revlimid, a blood cancer treatment, has been a significant contributor to Dr. Reddy’s revenue, but the company is preparing for a decline in sales as other generic versions enter the market.
To mitigate this impact, Dr. Reddy’s is counting on its biosimilars business, which involves developing and marketing copies of biologic drugs. The company has a robust pipeline of biosimilars, including treatments for cancer, autoimmune disorders, and other diseases. Biosimilars have become a key growth driver for Dr. Reddy’s, with sales increasing by 25% in the last fiscal year.
Another area of focus for Dr. Reddy’s is the rollout of its new weight-loss drug, which has shown promising results in clinical trials. The company is planning to launch the drug in the US market, where the demand for obesity treatments is high. Dr. Reddy’s is also exploring partnerships and collaborations to expand its reach in the global market.
In addition to biosimilars and the weight-loss drug, Dr. Reddy’s is also investing in its generic business, with a focus on complex generics and injectables. The company has a strong presence in the US generic market and is looking to expand its portfolio of products.
Dr. Reddy’s CEO, Erez Israeli, stated that the company is well-prepared for the loss of exclusivity for Revlimid and is confident about its growth prospects. He emphasized that the company’s diversified portfolio and strong research and development capabilities will help drive growth in the coming years.
Overall, Dr. Reddy’s is taking a proactive approach to address the challenges posed by the expiration of its exclusivity for Revlimid. By focusing on biosimilars, the weight-loss drug, and its generic business, the company is positioning itself for long-term growth and success. With a strong pipeline of products and a commitment to innovation, Dr. Reddy’s is well-placed to maintain its position as a leading player in the global pharmaceutical industry. The company’s ability to adapt to changing market dynamics and its focus on emerging opportunities will be key to its success in the coming years.
Dr Reddy’s and Eternal Gain Attention as KPI Green Witnesses Significant Uptick
KPI Green Energy Ltd. has reported impressive financial results for the third quarter, with a 39.4% year-over-year increase in net profit to ₹118 crore. The company’s revenue also saw a significant rise of 44.6% to ₹663 crore during the quarter. Additionally, the company’s EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) jumped 72.2% to ₹236 crore, resulting in an expanded EBITDA margin of 35.6% compared to 29.9% in the same period last year.
This strong performance by KPI Green Energy sets a positive tone for the upcoming earnings season in India, where over 60 listed companies are scheduled to declare their Q3 results. Some notable companies that will be reporting their results include Dr. Reddy’s Laboratories Ltd., Eternal (the parent company of Zomato), Thangamayil Jewellery Ltd., UTI Asset Management Company Ltd., PNB Housing Finance Ltd., and Tata Communications Ltd.
The market’s reaction to these earnings reports will be closely watched, as a strong performance across various sectors could boost investor confidence and potentially lead to a rally in the market. On the other hand, widespread misses in earnings expectations could trigger a correction in the market. Analysts will be carefully analyzing these results to gauge consumer demand, input costs, and overall corporate profitability in the current economic climate.
The earnings season is a critical period for investors, as it provides valuable insights into the performance of various companies and sectors. A strong earnings season could lead to increased investment in the market, while a weak performance could lead to a decline in investor sentiment. As such, all eyes will be on the earnings reports of these companies, and the market’s reaction will be closely watched in the coming days.
Indian Pharma Q3 Preview: Strong Domestic Formulations Segment to Offset US Pricing Challenges – scanx.trade
The Indian pharmaceutical industry is expected to experience a mixed bag in the third quarter of the year, with domestic formulations likely to counterbalance the pressure from pricing in the US market. The sector’s growth is anticipated to be driven by a strong performance in the domestic market, which is expected to offset the decline in exports to the US.
In the US, the Indian pharma industry is facing significant pricing pressure due to increasing competition and consolidation among buyers. This has resulted in a decline in exports, which is likely to continue in the third quarter. However, the domestic market is expected to witness a strong growth, driven by increasing demand for pharmaceuticals and a favorable regulatory environment.
The domestic formulations market is expected to grow at a rate of 10-12% in the third quarter, driven by the increasing demand for chronic therapies such as diabetes, cardiovascular, and respiratory diseases. The government’s initiatives to increase healthcare spending and improve access to medicines are also expected to boost demand.
On the other hand, the US market is expected to remain challenging due to pricing pressure and increasing competition. The US FDA has also become more stringent in its approval process, which is affecting the launch of new products. However, some companies are expected to benefit from the launch of new products and the resolution of regulatory issues.
The Indian pharma industry is also expected to benefit from the trend of pharmaceutical companies outsourcing their manufacturing to India. This is due to the country’s cost-competitive manufacturing capabilities and skilled workforce. The government’s initiatives to promote pharmaceutical manufacturing, such as the “Pharma Vision 2020” plan, are also expected to attract investments in the sector.
Overall, the Indian pharma industry is expected to witness a mixed performance in the third quarter, with domestic formulations driving growth and the US market remaining challenging. However, the long-term outlook for the industry remains positive, driven by the increasing demand for pharmaceuticals and the government’s initiatives to promote the sector.
Key players such as Sun Pharmaceutical, Cipla, and Dr. Reddy’s Laboratories are expected to perform well in the domestic market, while companies such as Aurobindo Pharma and Lupin are expected to benefit from their US businesses. The industry’s performance will also depend on the outcome of the US elections and the resulting policies, which could impact the pharmaceutical sector.
Dr Reddy’s introduces generic version of antihistamine eye drops to the US market
Dr. Reddy’s Laboratories has launched an over-the-counter (OTC) eye drop solution, Olopatadine Hydrochloride Ophthalmic Solution, in the US market. The solution is a generic equivalent of Extra Strength Pataday Once-Daily Relief, which is used to provide temporary relief from itchy eyes caused by pollen, ragweed, grass, animal hair, and dander. The launch was approved by the US Food and Drug Administration (USFDA).
According to Milan Kalawadia, CEO of North America Generics at Dr. Reddy’s Laboratories, the launch is a significant addition to the company’s existing portfolio in the OTC eye-care space. The company already offers Olopatadine Hydrochloride Ophthalmic Solution, and this new launch further expands its presence in the market. Kalawadia also highlighted the company’s capabilities in bringing store-brand equivalents of OTC brands to the US market, citing the first-to-market launch as a testament to these capabilities.
The Pataday brand, which Dr. Reddy’s solution is equivalent to, had significant sales in the US market, with approximately $69.9 million in sales over the 52-week period ending December 27, 2025. This indicates a substantial market demand for the product, and Dr. Reddy’s launch is likely to capitalize on this demand.
The launch of Olopatadine Hydrochloride Ophthalmic Solution is a strategic move by Dr. Reddy’s to expand its presence in the US OTC market. The company’s ability to bring generic equivalents of popular brands to the market can help increase accessibility and affordability of these products for consumers. With its strong portfolio in the OTC eye-care space, Dr. Reddy’s is well-positioned to compete in the market and provide consumers with high-quality, affordable options for their eye care needs.
Overall, the launch of Dr. Reddy’s Olopatadine Hydrochloride Ophthalmic Solution is a significant development in the US OTC market, and the company’s capabilities in bringing generic equivalents to the market are likely to have a positive impact on consumers and the industry as a whole.
Dr. Reddy’s Laboratories has been issued a pre-approval inspection letter from the USFDA for its biologics facility located in Hyderabad.
Dr. Reddy’s Laboratories has received a Pre-Approval Inspection (PAI) letter from the US Food and Drug Administration (USFDA) for its biologics facility located in Hyderabad, India. This letter indicates that the USFDA has completed its inspection of the facility and has found it to be compliant with the required standards.
The USFDA conducts pre-approval inspections to ensure that manufacturing facilities meet the necessary regulatory requirements before approving a new drug application. The inspection is a critical step in the approval process, and receiving a PAI letter is a significant milestone for Dr. Reddy’s Laboratories.
The Hyderabad biologics facility is a state-of-the-art manufacturing site that produces a range of biological products, including monoclonal antibodies and other biologic drugs. The facility has been designed to meet the highest international standards of quality and safety, and the USFDA’s pre-approval inspection is a testament to the facility’s compliance with these standards.
The receipt of the PAI letter is a positive development for Dr. Reddy’s Laboratories, as it brings the company one step closer to receiving approval for its biologic products in the US market. The company has been expanding its presence in the biologics market in recent years, and this development is expected to further strengthen its position in this segment.
The USFDA’s inspection process is rigorous and thorough, and the fact that Dr. Reddy’s Laboratories has received a PAI letter suggests that the facility has met the required standards. The company will now await the final approval from the USFDA, which is expected to be granted in the coming months.
The approval of Dr. Reddy’s biologics facility by the USFDA is significant not only for the company but also for the Indian pharmaceutical industry as a whole. It demonstrates the capability of Indian companies to meet international standards of quality and safety, and it is expected to boost the confidence of global regulatory agencies in the Indian pharmaceutical industry.
In conclusion, the receipt of the PAI letter by Dr. Reddy’s Laboratories is a significant development that brings the company closer to receiving approval for its biologic products in the US market. The company’s biologics facility in Hyderabad has been found to be compliant with the required standards, and the final approval from the USFDA is expected to be granted in the coming months. This development is expected to further strengthen Dr. Reddy’s position in the biologics market and boost the confidence of global regulatory agencies in the Indian pharmaceutical industry.
Stock Market Updates for Dr. Reddy’s Laboratories
Recent Updates
Dr. Reddy’s introduces Hevaxin, India’s inaugural Hepatitis E vaccine approved by the DCGI, specifically designed for adult use.
Dr. Reddy’s Laboratories has launched Hevaxin, a novel recombinant vaccine for the prevention of Hepatitis E virus (HEV) infection in India. This vaccine is the only one approved by the Drug Controller General of India (DCGI) for active immunization against HEV infection in adults aged 18 to 65 years. Clinical studies have shown that Hevaxin provides long-lasting immunity and has a favorable safety and tolerability profile.
Hepatitis E is a significant public health concern in India, causing a substantial proportion of acute viral hepatitis and acute liver failure cases. The World Health Organization (WHO) estimates that the infection affects around 20 million people globally each year, resulting in 3.4 million symptomatic cases, 70,000 deaths, and 3,000 stillbirths. In India, the disease burden is particularly high among vulnerable groups such as women of childbearing age, individuals with chronic liver disease, immunocompromised patients, and those preparing for organ transplantation.
The launch of Hevaxin addresses a critical unmet need for patients at high risk of severe outcomes, including acute-on-chronic liver failure and high fatality rates. Dr. Reddy’s aims to provide a first-in-class preventive option and support the National Viral Hepatitis Control Programme, which seeks to reduce the morbidity and mortality associated with Hepatitis E in India. The company has partnered with Shenzhen Mellow Hope Pharm and Urihk Pharmaceutical for the marketing and distribution of Hevaxin in the domestic market.
The launch of Hevaxin aligns with national efforts to reduce the burden of hepatitis A and E, as well as ambitious targets for hepatitis B and C elimination by 2030. According to M.V. Ramana, CEO of Branded Markets (India and Emerging Markets) at Dr. Reddy’s, the introduction of Hevaxin will provide a critical tool in the fight against Hepatitis E in India. With its favorable safety profile and long-lasting immunity, Hevaxin has the potential to make a significant impact on public health in India and support the country’s efforts to control and eliminate hepatitis.
Biotech Healthcare Group names Pankaj Phatak as its new Vice President of Human Resources, as reported by ETHRWorld.
Pankaj Phatak has been appointed as the Vice President of Human Resources at Biotech Healthcare Group. In this role, he will be responsible for driving the HR function globally. Phatak expressed his excitement about the new opportunity, stating that he looks forward to advancing a purpose-driven global people agenda and enabling access to innovation to serve people for a better life.
Prior to joining Biotech Healthcare, Phatak was associated with Dr. Reddy’s Laboratories, where he worked as the Director and Group HR Head for Central Functions – Global Manufacturing Operations. He had been with Dr. Reddy’s Laboratories since 2003, making it a long-standing tenure of over 22 years.
Before joining Dr. Reddy’s Laboratories, Phatak worked at Cipla for approximately two years. His experience and expertise in the field of human resources will likely be valuable assets to Biotech Healthcare Group as they move forward.
Phatak’s appointment was announced on January 2, 2026, and he shared the news on his LinkedIn profile. The move is expected to bring new perspectives and ideas to the HR function at Biotech Healthcare Group, and Phatak’s global experience will likely be beneficial in driving the company’s people agenda.
As Vice President of Human Resources, Phatak will play a key role in shaping the company’s HR strategies and initiatives. His focus on advancing a purpose-driven global people agenda suggests that he will prioritize creating a positive and supportive work environment that enables employees to thrive and contribute to the company’s success.
Overall, Phatak’s appointment is a significant development for Biotech Healthcare Group, and his expertise and experience are expected to make a positive impact on the company’s HR function. With his leadership, the company is likely to see improvements in its people management and HR initiatives, which will ultimately contribute to its overall success and growth.
USFDA deals a blow to Dr Reddy’s biosimilar denosumab AVT03 following an inspection of the manufacturing facility.
Dr. Reddy’s Laboratories has faced a setback in its efforts to bring its denosumab biosimilar, AVT03, to the US market. The US Food and Drug Administration (USFDA) has issued a warning letter to the company after conducting an inspection of its manufacturing facility. The inspection revealed several issues with the plant’s quality control systems, which have raised concerns about the safety and efficacy of the biosimilar.
Denosumab is a monoclonal antibody used to treat osteoporosis, bone metastases, and giant cell tumor of bone. The reference product, Prolia, is marketed by Amgen and has been a major commercial success. Dr. Reddy’s AVT03 is a biosimilar version of Prolia, which the company had hoped to launch in the US market.
The USFDA inspection, which took place in 2022, identified several issues with the plant’s quality control systems, including inadequate procedures for ensuring the sterility of the product, insufficient testing of the product’s stability, and inadequate training of personnel. The agency also found that the company had failed to investigate and correct deviations from its quality control procedures.
As a result of the inspection, the USFDA has issued a warning letter to Dr. Reddy’s, which outlines the specific issues that need to be addressed. The company must now take corrective action to address these issues and demonstrate to the agency that its quality control systems are adequate to ensure the safety and efficacy of AVT03.
The setback is a significant blow to Dr. Reddy’s, which had been hoping to launch AVT03 in the US market in the near future. The company will now need to take time to address the issues raised by the USFDA and resubmit its application for approval. This could delay the launch of AVT03 by several months or even years, depending on the complexity of the issues and the time it takes to resolve them.
The news is also a disappointment for patients who were hoping to have access to a more affordable version of denosumab. Biosimilars like AVT03 have the potential to significantly reduce the cost of biologic therapies, making them more accessible to patients who need them. However, the USFDA’s strict regulatory requirements are in place to ensure the safety and efficacy of these products, and Dr. Reddy’s must now take the necessary steps to demonstrate that AVT03 meets these standards.
Gurupyar Reddy, Production Complex Injections Head at Dr Reddy’s Laboratories
The Vizag Pharma Summit 2025 is scheduled to take place on December 17th, 2025, at the Fairfield by Marriott in Vizag. The event will feature a speaker, Mr. Gurupyar Reddy, who is the Head of Production Complex Injections at Dr. Reddy’s Laboratories. Mr. Reddy will be discussing the topic of generic complex injections.
The key takeaway from Mr. Reddy’s presentation is that advanced drug delivery systems, such as Nanotechnology-based Drug Delivery Systems (NDDS), are no longer optional in the pharmaceutical industry. Instead, they are critical to improving the efficacy of treatments, patient outcomes, and the future value of pharmaceutical innovation. This suggests that the industry is shifting towards more sophisticated and targeted approaches to drug delivery, which can enhance the effectiveness of treatments and improve patient care.
The Vizag Pharma Summit 2025 is likely to be an important event for professionals in the pharmaceutical industry, as it will provide a platform for discussion and knowledge-sharing on the latest trends and advancements in the field. The summit may cover a range of topics related to pharmaceuticals, including research and development, manufacturing, and regulatory affairs.
The focus on generic complex injections and advanced drug delivery systems reflects the growing importance of these areas in the pharmaceutical industry. Generic complex injections are a type of medication that is designed to be more effective and have fewer side effects than traditional drugs. They often involve the use of advanced technologies, such as nanoparticles and liposomes, to deliver the active ingredient to the target site in the body.
Overall, the Vizag Pharma Summit 2025 is an event that is likely to be of interest to anyone involved in the pharmaceutical industry, from researchers and manufacturers to regulators and healthcare professionals. The summit will provide a valuable opportunity for networking, learning, and discussion, and will help to shape the future of the industry. With its focus on advanced drug delivery systems and generic complex injections, the event is likely to be an important milestone in the development of new and innovative treatments for a range of diseases and conditions.
Delhi High Court prohibits Dr. Reddy’s from using the ‘SUN’ trademark on sunscreen product labels.
The Delhi High Court has issued a restraining order against Dr. Reddy’s Laboratories, preventing the company from using the ‘SUN’ mark on their sunscreen product labels. This decision comes after a lawsuit was filed by Sun Pharmaceutical Industries, which claimed that Dr. Reddy’s was infringing on their trademark rights.
Sun Pharmaceutical Industries had been using the ‘SUN’ mark for their various pharmaceutical products, including sunscreens, and had registered the trademark in 2002. The company argued that Dr. Reddy’s use of the ‘SUN’ mark on their sunscreen labels would cause confusion among consumers and dilute the distinctiveness of their trademark.
The Delhi High Court agreed with Sun Pharmaceutical Industries, stating that Dr. Reddy’s use of the ‘SUN’ mark was likely to cause confusion among consumers. The court also noted that Dr. Reddy’s had not provided any evidence to show that they had been using the ‘SUN’ mark prior to Sun Pharmaceutical Industries’ registration of the trademark.
As a result of the court’s decision, Dr. Reddy’s will be required to remove the ‘SUN’ mark from their sunscreen product labels and packaging. The company will also be prohibited from using any other marks that are similar to the ‘SUN’ mark, in order to avoid causing confusion among consumers.
This decision highlights the importance of protecting intellectual property rights, particularly in the pharmaceutical industry where consumer safety and trust are paramount. It also demonstrates the proactive approach taken by the Delhi High Court in enforcing trademark rights and preventing infringement.
The court’s decision is a significant victory for Sun Pharmaceutical Industries, which had invested significant time and resources into building their brand and protecting their trademark. The company can now continue to use the ‘SUN’ mark without fear of confusion or dilution, and can focus on providing high-quality products to consumers.
In contrast, Dr. Reddy’s will need to rebrand their sunscreen products and find alternative names or marks that do not infringe on Sun Pharmaceutical Industries’ trademark rights. This may require significant investments in marketing and advertising, as well as changes to their product packaging and labeling.
Overall, the Delhi High Court’s decision in this case emphasizes the importance of respecting intellectual property rights and the need for companies to conduct thorough trademark searches before launching new products or using new marks. It also highlights the role of the courts in protecting trademark rights and preventing infringement, and the need for companies to be vigilant in defending their intellectual property.
The input string did not conform to the expected format.
An error occurred during the execution of a web request, resulting in an unhandled exception. The exception was a System.FormatException, which indicates that the input string was not in the correct format. This error occurred in the Page_Load method of the NewsDetails.aspx.cs file, specifically on line 140.
The stack trace provides more information about the origin and location of the exception. It shows that the error occurred in the Pharmabiz.NewsDetails.Page_Load method, which is part of the NewsDetails.aspx.cs file. The method is called when the page is loaded, and it is responsible for initializing the page and its controls.
The error is likely due to the fact that the input string is not in the correct format, which is causing the Page_Load method to fail. The exact cause of the error is not specified, but it could be due to a variety of factors, such as invalid user input, incorrect data formatting, or a bug in the code.
The version information provided shows that the error occurred on a server running Microsoft.NET Framework version 4.0.30319 and ASP.NET version 4.8.4676.0. This information can be useful for debugging and troubleshooting purposes.
To resolve the error, the developer will need to review the code and identify the cause of the exception. This may involve checking the input data, validating user input, and ensuring that the data is in the correct format. Additionally, the developer may need to modify the code to handle exceptions and errors more robustly, to prevent similar errors from occurring in the future.
In general, a System.FormatException is a common error that can occur when working with strings and data formatting. It is often caused by incorrect or invalid data, and can be resolved by validating and sanitizing user input, and ensuring that data is in the correct format before attempting to process it. By reviewing the code and identifying the cause of the exception, the developer can take steps to resolve the error and prevent it from occurring again in the future.
Former Dr. Reddy’s facility in Shreveport gets new signage: Frymaster.
A new sign has been erected at the former Dr. Reddy’s plant in Shreveport, indicating that Frymaster, a commercial fryer manufacturer, will be occupying the space. This development marks a significant turning point for the facility, which was previously home to Dr. Reddy’s, a pharmaceutical company. The sign’s installation suggests that Frymaster is moving forward with its plans to utilize the plant, potentially bringing new economic activity and job opportunities to the area.
The former Dr. Reddy’s plant, located in Shreveport, has been vacant for some time, leaving the community wondering about its future. With Frymaster’s sign going up, it appears that the facility will be repurposed for the manufacture of commercial fryers, which are used in the food service industry. This change in occupancy could have a positive impact on the local economy, as Frymaster may create new jobs and stimulate growth in the region.
Frymaster, a leading manufacturer of commercial fryers, has a long history of producing high-quality equipment for the food service industry. The company’s products are used in restaurants, cafes, and other food establishments around the world. By establishing a presence in Shreveport, Frymaster may be able to expand its operations, increase production, and better serve its customers in the southern United States.
The arrival of Frymaster in Shreveport is likely to be welcomed by local officials and residents, who have been eager to see the former Dr. Reddy’s plant reused. The plant’s revitalization could also have a positive impact on the surrounding area, potentially leading to increased investment and development in the region. As Frymaster begins to occupy the facility, the community will be watching with interest to see how the company’s presence will shape the local economy and job market.
While the exact details of Frymaster’s plans for the facility are not yet clear, the installation of the sign is a promising sign for the future of the plant and the local community. As the company moves forward with its operations, it is likely that more information will become available about its intentions and the potential benefits of its presence in Shreveport. For now, the sign serves as a symbol of hope and renewal for the area, suggesting that the former Dr. Reddy’s plant will once again be a hub of economic activity.
The U.S. FDA has granted approval to Dr. Reddy’s, a leading pharmaceutical company, to manufacture and distribute a treatment for gonorrhea.
The US Food and Drug Administration (FDA) has approved two new oral medicines, Nuzolvence (zoliflodacin) and Blujepa (gepotidacin), to treat gonorrhea, a common sexually transmitted infection (STI) that is increasingly resistant to existing treatments. The World Health Organization (WHO) has classified the bacteria that causes gonorrhea, Neisseria gonorrhoeae, as a “high priority” pathogen due to its growing resistance to antibiotics. Gonorrhea is spread through sexual contact and can cause painful urination, bleeding, and discharge in the genital area, as well as infertility and complications if left untreated.
The two new drugs offer a critical addition to the limited treatment options available for gonorrhea. Nuzolvence, which is administered as a single oral dose, was developed by Entasis Therapeutics in partnership with the Global Antibiotic Research and Development Partnership (GARDP), a nonprofit organization. Blujepa, also an oral tablet, was developed by GSK. Indian pharmaceutical company Dr. Reddy’s is working to obtain market authorization for Nuzolvence in Thailand and South Africa, where clinical trials were conducted.
The WHO estimates that there were 82.4 million new cases of gonorrhea among adults aged 15-49 in 2020. The rise in cases is attributed in part to the increased use of Pre-Exposure Prophylaxis (PrEP) for HIV prevention, which does not protect against other STIs. The approval of these new drugs is a significant milestone in the treatment of gonorrhea, and GARDP is working to ensure that they are accessible to those who need them, particularly in low- and middle-income countries.
GARDP’s R&D Drug and Treatment Project Leader, Pierre Damar, notes that limiting the clinical use of zoliflodacin to treating gonorrhea will help to delay the emergence of resistance and prolong the effectiveness of the drug. The organization is exploring partnerships with governments and other stakeholders to ensure that the drug is available and accessible to those who need it. With the rise in gonorrhea cases, the approval of these new drugs is a crucial step in addressing this growing public health concern.